NEW YORK, NY / ACCESSWIRE / March 24, 2015 / Market Exclusive announces that H.C. Wainwright & Co. continues to rate the shares of GenSpera, Inc. (OTCQB: GNSZ) as Buy with a 12-month price target of $2.00 per share.

Writing on Genspera's potential expansion plans, H.C Wainwrights & Co. analyst Swayampakula Ramakanth wrote, "We believe management's strategy is to secure development and commercialization partners to help bring mipsagargin to the market both in the U.S. and in Asia? We believe there is significant market potential for mipsagargin in [China and Japan], as the incidence rate of liver cancer in China and Japan is approximately 400,000 cases per year, compared to approximately 36,000 cases in the US."

GenSpera, Inc., headquartered in San Antonio, Texas, is a biotechnology company specializing in the development of targeted prodrug agents for the treatment of various solid cancers.

About Market Exclusive

Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

SOURCE: Market Exclusive